Viyash Scientific Limited has reported its financial results for the quarter and year ended March 31, 2026. The company achieved ₹3,724.90 million in standalone revenue for the quarter, with ₹13,820.60 million for the fiscal year. Key developments include the approval of a new Employee Stock Option Scheme for 1,30,98,000 options and the adoption of updated Articles of Association to align with the Companies Act, 2013. No dividend was recommended for FY 2025-26.
Financial Performance Overview
For the fourth quarter of FY 2025-26, Viyash Scientific recorded standalone revenue from operations of ₹3,724.90 million, bringing the total annual standalone revenue to ₹13,820.60 million. The consolidated results reflect a strong performance, with quarterly revenue at ₹9,199.60 million and an annual consolidated revenue of ₹34,203.10 million. The Board of Directors has decided not to recommend any dividend for the 2025-26 fiscal year, opting to prioritize the conservation of resources for future growth.
Strategic Corporate Developments
In a significant move to incentivize its workforce, the Board has approved the grant of 1,30,98,000 stock options under the Viyash Scientific Limited Employee Stock Option Scheme 2026. This allocation represents up to 2.8% of the company’s post-amalgamation paid-up share capital on a fully diluted basis, with an exercise price set at ₹101 per option. The vesting period for these options will be a minimum of one year from the date of grant.
Corporate Governance and Operational Updates
The company is undergoing an administrative overhaul to ensure compliance with modern corporate standards. The Board has proposed the adoption of a new set of Articles of Association. This update is designed to align the company’s internal regulations with the Companies Act, 2013, replacing the older framework based on the 1956 Act. Additionally, the company confirmed that it does not qualify as a ‘Large Corporate’ entity for the 2025-26 financial year.
Business Highlights
Viyash Scientific continues to focus on its core pharmaceutical operations. A notable operational success during the year was the sale of land and assets at the Parwada, Visakhapatnam facility, which resulted in a profit of ₹42.60 million. Management remains committed to monitoring new labor codes and market developments to maintain operational efficiency.
Source: BSE
